Tracy Kleinheinz

Title: Tracy Kleinheinz: Innovator in Cancer Treatment

Introduction

Tracy Kleinheinz is a notable inventor based in South San Francisco, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceutical compounds. Her work focuses on inhibiting specific proteins that play a crucial role in various diseases.

Latest Patents

Tracy Kleinheinz holds a patent for "Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a][1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer." This patent describes compounds and salts that are effective in inhibiting target polypeptides and proteins, particularly bromodomain proteins such as BRD4. The disclosure also includes pharmaceutical compositions comprising these compounds and methods for treating various bromodomain-mediated diseases or disorders.

Career Highlights

Throughout her career, Tracy has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to develop her expertise in drug discovery and development, particularly in the area of cancer therapeutics.

Collaborations

Tracy has collaborated with esteemed colleagues such as Robert Anthony Blake and Peter Scott Dragovich. These partnerships have contributed to her success in advancing innovative solutions for cancer treatment.

Conclusion

Tracy Kleinheinz is a pioneering inventor whose work in developing bromodomain inhibitors has the potential to transform cancer treatment. Her dedication to research and collaboration with industry leaders highlights her significant impact in the field of pharmaceuticals.